Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension

Plaque Psoriasis ◽

Controlled Trial ◽

Open Label ◽

Weekly Administration ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients with Dementia with Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial

American Journal of Geriatric Psychiatry ◽

10.1016/j.jagp.2021.07.002 ◽

2021 ◽

Author(s):

Toshinari Odawara ◽

Kazuko Hasegawa ◽

Ritsuko Kajiwara ◽

Hisao Takeuchi ◽

Masaaki Tagawa ◽

...

Keyword(s):

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Randomized Controlled ◽

25853 Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase

10.1016/j.jaad.2021.06.313 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB72

Author(s):

Elke Weisshaar ◽

Jacek C. Szepietowski ◽

Thomas R. Sciascia ◽

Gil Yosipovitch ◽

Sonja Ständer

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study

Rheumatology ◽

10.1093/rheumatology/keu101.024 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i96-i96 ◽

Cited By ~ 1

Author(s):

Edward Keystone ◽

Robert Landewé ◽

Ronald van Vollenhoven ◽

Bernard Combe ◽

Vibeke Strand ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Certolizumab Pegol ◽

Extension Study ◽

Open Label ◽

Safety And Efficacy ◽

Randomized Controlled ◽

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)70394-0 ◽

2007 ◽

Vol 2007 ◽

pp. 101-102

Author(s):

B.H. Thiers

Keyword(s):

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

10.1016/j.jaad.2006.05.027 ◽

2006 ◽

Vol 55 (4) ◽

pp. 598-606 ◽

Cited By ~ 322

Author(s):

Kenneth B. Gordon ◽

Richard G. Langley ◽

Craig Leonardi ◽

Darryl Toth ◽

M. Alan Menter ◽

...

Keyword(s):

Clinical Response ◽

Controlled Trial ◽

Severe Psoriasis ◽

Extension Study ◽

Open Label ◽

Double Blind ◽

Randomized Controlled ◽

Open Label Extension ◽

Adalimumab Treatment

Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open Open-Label Extension Phase

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.29 ◽

2021 ◽

Vol 5 (1) ◽

pp. s29

Author(s):

Elke Weisshaar ◽

Thomas Sciascia ◽

Sonja Stander

Keyword(s):

Extended Release ◽

Controlled Trial ◽

Extension Phase ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Prurigo Nodularis ◽

Randomized Controlled ◽

Abstract not available.

Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5‐Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open‐Label Extension of a Randomized Controlled Trial

Journal of Bone and Mineral Research ◽

10.1002/jbmr.4453 ◽

2021 ◽

Author(s):

Andrew Grey ◽

Mark J Bolland ◽

Anne Horne ◽

Borislav Mihov ◽

Greg Gamble ◽

...

Keyword(s):

Bone Mineral Density ◽

Bone Turnover ◽

Older Women ◽

Bone Mineral ◽

Controlled Trial ◽

Mineral Density ◽

Open Label ◽

Randomized Controlled ◽

Efficacy and safety of apremilast with or without topical or phototherapy: Subanalysis of the population with < PASI-75 in the ESTEEM 1 phase 3, randomized, controlled trial in patients with moderate to severe plaque psoriasis

10.1016/j.jaad.2016.02.963 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB246 ◽

Cited By ~ 1

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Randomized Controlled

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

10.1016/j.jaad.2015.05.013 ◽

2015 ◽

Vol 73 (3) ◽

pp. 400-409 ◽

Cited By ~ 287

Author(s):

Diamant Thaçi ◽

Andrew Blauvelt ◽

Kristian Reich ◽

Tsen-Fang Tsai ◽

Francisco Vanaclocha ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Severe Plaque Psoriasis ◽

Randomized Controlled